U.S. markets closed

Jounce Therapeutics, Inc. (JNCE)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
7.27+0.58 (+8.67%)
At close: 1:00PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Short-term KST

Short-term KST

Previous Close6.69
Open6.77
Bid6.88 x 900
Ask7.44 x 800
Day's Range6.77 - 7.39
52 Week Range2.85 - 11.72
Volume272,207
Avg. Volume1,301,434
Market Cap289.72M
Beta (5Y Monthly)1.67
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Undervalued
54% Est. Return
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Jounce Therapeutics, Inc. (JNCE) Q3 2020 Earnings Call Transcript
    Motley Fool

    Jounce Therapeutics, Inc. (JNCE) Q3 2020 Earnings Call Transcript

    Speaking on today's call will be our CEO, and President, Dr. Rich Murray, who will discuss our progress and key milestones followed by our CMO, Beth Trehu, who will provide an update on our clinical activities. Kim Drapkin will review our third quarter financial results. Before we begin, I would like to remind everyone that today's discussion will include statements about our future expectations, plans, and prospects that constitute forward-looking statements for the purposes of the Safe Harbor provisions under the Private Securities Litigation Reform Act of 1995.

  • Why Jounce Therapeutics Stock Is Crashing Today
    Motley Fool

    Why Jounce Therapeutics Stock Is Crashing Today

    Shares of Jounce Therapeutics (NASDAQ: JNCE) were crashing 20.2% lower as of 11:42 a.m. EST on Monday. The big drop came after the company announced that it would not continue patient enrollment in the Emerge phase 2 trial evaluating vopratelimab (vopra) in combination with Bristol Myers Squibb's Yervoy in treating non-small cell lung cancer (NSCLC). This news hit the biotech stock especially hard because vopra is Jounce's lead pipeline candidate.

  • If You Had Bought Jounce Therapeutics (NASDAQ:JNCE) Shares A Year Ago You'd Have Earned 147% Returns
    Simply Wall St.

    If You Had Bought Jounce Therapeutics (NASDAQ:JNCE) Shares A Year Ago You'd Have Earned 147% Returns

    Unfortunately, investing is risky - companies can and do go bankrupt. But if you pick the right stock, you can make a...